210 related articles for article (PubMed ID: 26974314)
1. Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis.
Guo C; Zhang C; Liu J; Tong L; Huang G
Nucl Med Commun; 2016 Jul; 37(7):675-88. PubMed ID: 26974314
[TBL] [Abstract][Full Text] [Related]
2. Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings.
Collarino A; de Koster EJ; Valdés Olmos RA; de Geus-Oei LF; Pereira Arias-Bouda LM
Clin Breast Cancer; 2018 Feb; 18(1):9-18. PubMed ID: 28728876
[TBL] [Abstract][Full Text] [Related]
3. Tc-99m sestamibi scintimammography for the diagnosis of breast cancer: meta-analysis and meta-regression.
Xu HB; Li L; Xu Q
Nucl Med Commun; 2011 Nov; 32(11):980-8. PubMed ID: 21956488
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
5. Dual phase qualitative and quantitative 99mTc-MIBI scintimammography for predicting response to neoadjuvant chemotherapy in breast cancer.
Zaman MU; Nasir Z; Raza T; Hashmi H; Hashmi A; Fatima N
J Coll Physicians Surg Pak; 2009 Mar; 19(3):173-8. PubMed ID: 19268018
[TBL] [Abstract][Full Text] [Related]
6. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
Mezi S; Primi F; Capoccetti F; Scopinaro F; Modesti M; Schillaci O
Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988
[TBL] [Abstract][Full Text] [Related]
7. Breast-specific gamma camera imaging with
Zhang A; Li P; Liu Q; Song S
Hell J Nucl Med; 2017; 20(1):26-35. PubMed ID: 28315905
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
9. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K
Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of response to neoadjuvant chemotherapy using breast scintigraphy in breast cancer].
Baena-Cañada JM; Partida-Palma F; Palomo-González MJ; Benítez E; Rueda-Ramos A; García-Curiel A
Med Clin (Barc); 2005 Nov; 125(16):601-5. PubMed ID: 16287568
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL
J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
[TBL] [Abstract][Full Text] [Related]
13. Contribution of 99mTc-anti-carcinoembryonic antigen antibody and 99mTc-sestamibi scintimammography in the evaluation of high risk palpable breast lesions.
Sanidas EE; Koukouraki S; Velidaki A; Manios A; Stathopoulos E; De Bree E; Kafousi M; Kodogiannis E; Karkavitsas N; Tsiftsis DD
Nucl Med Commun; 2003 Mar; 24(3):291-6. PubMed ID: 12612470
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake.
Marshall C; Eremin J; El-Sheemy M; Eremin O; Griffiths PA
Nucl Med Commun; 2005 Jan; 26(1):9-15. PubMed ID: 15604942
[TBL] [Abstract][Full Text] [Related]
15. Technetium-99m methoxyisobutylisonitrile scintimammography for monitoring and early prediction of breast cancer response to neoadjuvant chemotherapy.
Novikov SN; Kanaev SV; Petr KV; Tatyana SY; Elena TA; Ludmila JA; Nikolay ID; Zhanna BV; Pavel KI
Nucl Med Commun; 2015 Aug; 36(8):795-801. PubMed ID: 26011586
[TBL] [Abstract][Full Text] [Related]
16. Can scintimammography with (99m)Tc-MIBI identify multifocal and multicentric primary breast cancer?
Cwikla JB; Buscombe JR; Holloway B; Parbhoo SP; Davidson T; McDermott N; Hilson AJ
Nucl Med Commun; 2001 Dec; 22(12):1287-93. PubMed ID: 11711898
[TBL] [Abstract][Full Text] [Related]
17. Tc-99m MIBI in suspected recurrent breast cancer.
Cwikla JB; Kolasinska A; Buscombe JR; Hilson AJ
Cancer Biother Radiopharm; 2000 Aug; 15(4):367-72. PubMed ID: 11041021
[TBL] [Abstract][Full Text] [Related]
18. (99M)Technetium-sestamibi scintimammography in non-palpable breast lesions found on screening X-ray mammography.
Gommans GM; van der Zant FM; van Dongen A; Boer RO; Teule GJ; de Waard JW
Eur J Surg Oncol; 2007 Feb; 33(1):23-7. PubMed ID: 17126524
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Drucker MJ; Livingston RB
Cancer; 1999 Jun; 85(11):2410-23. PubMed ID: 10357412
[TBL] [Abstract][Full Text] [Related]
20. The comparison of dual phase Tc-99m MIBI and tc-99m MDP scintimammography in the evaluation of breast masses: preliminary report.
Arslan N; Ozturk E; Ilgan S; Narin Y; Dundar S; Tufan T; Pekcan M; Bayhan H
Ann Nucl Med; 2000 Feb; 14(1):39-46. PubMed ID: 10770579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
